Picard Medical Cuts Net Loss 16% on 39% Revenue Growth
Event summary
- Picard Medical reported Q2 2026 revenue growth of 39% to $3.0M, driven by U.S. sales.
- Net loss decreased 16% to $5.7M, while gross profit turned positive at $0.6M (20.9% margin).
- Year-to-date revenue increased 50% to $4.1M with $0.9M in gross profit.
- Completed a 1-for-50 reverse stock split to comply with NYSE American listing standards.
- Advanced preclinical development of the Emperor Total Artificial Heart platform.
The big picture
Picard Medical's improved financial performance reflects progress in its core artificial heart business, but the company remains deeply unprofitable. The strategic focus on next-generation technology and operational efficiency comes as the medical device sector faces increasing pressure to demonstrate long-term viability. The reverse stock split and NYSE compliance plan highlight ongoing governance challenges amid efforts to secure additional financing.
What we're watching
- Financial Stability
- Whether Picard Medical can sustain improved profitability amid rising R&D and operational expenses.
- Product Development
- The pace at which the Emperor TAH platform advances through preclinical development and regulatory approvals.
- Market Expansion
- How U.S. sales growth will offset European declines and drive overall revenue.